Bruker (FRA:BKD) Current Deferred Revenue: €386 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:BKD Bruker Corp FRA:BKD
84 GF Score
Price €49.76
GF Value €51.91
Valuation Fairly Valued
! 11 Warning Signs
View Full Analysis

What is Bruker Current Deferred Revenue?

Bruker FRA:BKD -1.74% 84 Current Deferred Revenue is €386 Mil as of Jun. 2026. GuruFocus rates FRA:BKD with a GF Score™ of 84/100 and a GF Value™ of €51.91 (Fairly Valued). The stock has 11 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Bruker's current deferred revenue for the quarter that ended in Jun. 2026 was €386 Mil.

Bruker Current Deferred Revenue Related Terms

Bruker Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Bruker's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bruker Current Deferred Revenue Chart

Bruker Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 297.27 349.47 366.80 421.73 376.87

Bruker Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 414.51 388.00 376.87 414.94 385.91
FRA:BKD
84GF Score
Bruker Corp FRA:BKD
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of €386 Mil mean?
Bruker (FRA:BKD) has a Current Deferred Revenue of €386 Mil as of Jun. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Bruker and its competitors.
Is Bruker's Current Deferred Revenue too high?
Bruker's current Current Deferred Revenue is €386 Mil. Overall, Bruker has a GF Score™ of 84/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bruker's Current Deferred Revenue compare to GKOS and BIO?
Bruker's Current Deferred Revenue of €386 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Medical Devices & Instruments company?
A good Current Deferred Revenue depends on the Medical Devices & Instruments industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Bruker and its competitors. Bruker's current Current Deferred Revenue is €386 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bruker stock overvalued right now?
Based on GuruFocus' analysis, Bruker (FRA:BKD) is currently considered Fairly Valued. The stock's GF Value™ is €51.91, compared to a current price of €49.76 — trading 4.1% below its estimated fair value. The current Current Deferred Revenue is €386 Mil. Bruker's overall GF Score™ is 84/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Bruker (FRA:BKD), the current Current Deferred Revenue is €386 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bruker (FRA:BKD) Overvalued in 2026?

Based on GuruFocus' analysis, Bruker stock appears to be undervalued. The current stock price of €49.76 is trading 4.1% below its estimated GF Value™ of €51.91. GuruFocus considers Bruker to be Fairly Valued.

Key valuation signals for FRA:BKD:

  • Current Deferred Revenue: €386 Mil
  • GF Value™: €51.91 vs. price of €49.76 (4.1% below fair value)
  • GF Score™: 84/100 with 11 warning signs

No single metric tells the full story. See the FRA:BKD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bruker Business Description

Address 40 Manning Road, Billerica, MA, USA, 01821
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies (BEST) . The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.
84GF Score

Get the complete analysis for FRA:BKD

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€49.76
Price
€51.91
GF Value